 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 5 of 44 
 TITLE PAGE  
 
 
 
Title:  A Multi -Center Clinical Trial to Evaluate the Efficacy of Two 
Acne Treatments  
Short Title : A Multi -Center Clinical Trial to Evaluate the  Efficacy of Two 
Acne Treatments  
Protocol number:  GLI.04.SPR.US10354  
Study phase:  Phase IV  
Sponsor:  Galderma Laboratories, L.P.  
14501 North Freeway  
Fort Worth, TX 76177  
USA 
Telephone: 1 -817-961-5000  
 
This study will be performed in compliance with applicable federal regulations and  Good Clinical 
Practice (GCP). This Clinical Study Protocol follows guidelines outlined by the International 
Conference on Harmonization (ICH) and Galderma Laboratories, L.P.  (GLLP).  
All the data provided to the investigat or and his/her staff and all data obtained through th is GLLP  
protocol will be regarded as confidential and proprietary in nature and should not be disclosed to 
any third party without GLLP ’s written consent.  
 
Effective Date:    11 February  2016  
 
 
 
  

 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 6 of 44 
 1. SYNOPSIS  
Title:  A Multi -Center Clinical Trial to Evaluate the Efficacy of Two Acne Treatments  
Protocol Number: GLI.04.SPR.US10354  
Study Period (Planned): Duration of subject participation is approximately 24 weeks 
(Screening/ Baseline , Week 1, Week 2, Week 6, Week 12, Week 18, and Week 24 ) 
Phase of Development: Phase IV  
Objectives:  
 To characterize the effect iveness  of the acne treatment in lesion count at week 1, week 
2, week 6, week 12, and week 24  as compared to baseline  and compare between 
treatmen ts 
 To characterize the effect iveness  of the acne treatment in Investigator’s Global 
Improvement Assessment at week 1, week 2, week 6, week 12, and week 24  as 
compared to baseline and compare between treatments  
 To characterize the effect  of the acne treatment in clinical grading of efficacy 
parameters through digital images at week 6 , week 12 , and week 24  as compared to 
baseline and compare between treatments  
 To characterize the effect of the acne treatment in subject  self-assessment 
questionnair e responses  at week 1, week 2, week 6 , week 12 , and week 24 as 
compared to baseline  and compare between treatments  
Overall Study Design:  
This is a multicenter, double -blind, randomized, control led clinical trial  to be conducted in the 
United States  at 4 testing facilities . The study will examine the effect  of 2 acne treatments 
(Product A when used once daily and Product B  when used 1 -3x a day ) for 24 weeks  in adult 
men and women 21  to 45 years of age  with mild to moderate facial acne, with at least 5 
inflammatory lesion s, and 10 – 100 non -inflammatory lesions at enrollment . Subjects meeting 
the inclusion/exclusion criteria ar e to be enrolled in the study. There will be up to 8  visits 
during the course of the study: Screening, Baseline, Week  1, Week 2, Week 6 , Week 12 , 
Week 18, and Week 24 .  
Number of Subjects Planned/Analyzed: Approximately 130 subjects will be enrolled to 
complete with 100 subjects  (50 per cell) . For the purposes of this protocol, enrolled is defined 
as a subject who has been consented, screened and eligibility has been verified.  
 
Each site is to enroll no more than 40 subjects, with at least 100 subjects expected to 
complete when combined.  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 7 of 44 
 Main Inclusion Criteria:  Men and women , 21 to 45 years of age with mild to moderate fa cial 
acne, at least 5 inflammatory lesions, and at least 10 – 100 non -inflammatory lesions .  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 8 of 44 
 Galderma Study Products:  
Study product:   Facial Clea nser   
Form:  Gel   
Instructions for Use:  massage a small amount onto wet skin. Rinse .  
Mode of Administration:   Topical  
Duration of Use : 24 Weeks  
-------------------------------------------------------------------------------------------------------------------------  
Galderma Study Products:  
Study product:   Product A   
Form:  Gel   
Instru ctions for Use:  Dispense a nickel size amount of product and apply as a thin layer to the 
entire face or any other affected areas of the skin once daily, after washing gently with a mild 
soap -less cleanser and drying the area.  
Mode of Administration:   Topical 
Duration of Use : 24 Weeks  
-------------------------------------------------------------------------------------------------------------------------  
Study product:   Product B  
Form:  Gel 
Instructions for Use:  Clean the skin tho roughly before applying this product. Cover the entire 
affected area with a thin layer one to three times daily. Because excessive drying of the skin may 
occur, start with one application daily, then gradually increase to two or three daily if needed or 
as directed by a doctor. If bothersome dryness or peeling occurs, reduce application to once a 
day or every other day.  
Mode of Administration:  Topical  
Duration of Use:  24 Weeks  
---------------------------------------------------- ---------------------------------------------------------------------  
Galderma Study Products:  
Study product:   Moisturizing Lotion   
Form:  Lotion   
Instructions for Use:  After applying the product, use moisturizer on the entire face. Apply as 
needed or as directed by a physician.   
Mode of Administration:   Topical  
Duration of Use : 24 Weeks  
 -------------------------------------------------------------------------------------------------------------------------  
Galderma Study Products:  
Study product:   Facial Moisturizer SPF 30    
Form:  Cream   
Instructions for Use:  Apply liberally 15 minutes before sun exposure.  Use a water resistant 
sunscreen if swimming or sweating. Reapply at least every 2 hours  
Mode of Administration:   Topical 
Duration of Use : 24 Weeks   
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 9 of 44 
 Criteria for Evaluation:  
All subjects who are enrolled and receive study products will be evaluable for safety analyses. 
All subjects who are enrolled, receive study products, and have at least one post treatment 
administr ation evaluation will be evaluable for intent -to-treat analyses.  
General instructions:  
Use all products as directed . Cleanser, test material, and moisturizer should be used as a 
regimen.  
Avoid extended periods of sun exposure, all use of tanning beds, and sunless tanning 
products for the duration of the study. Extra care should be taken to wear protective clothing, 
including sunglasses, and avoid sun exposure from 10 AM to 4 PM.  
Continue use of  all regular brands of color cosmetics, makeup remover, and use the assigned 
test material for the duration of the study.  Individuals must refrain from using any acne  
products and beginning the use of any new facial products other than the assigned test 
material. Use of moisturizing foundation will be acceptable as long as the subject has a history 
of safe usage of the foundation.  
 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 10 of 44 
 Assessment  Measure  
 Lesion count  Investigator  or designee  will count the inflammatory 
and non -inflammat ory lesions on each subject’s face  
 Investigator’s Global 
Assessment (IGA)  Investigator  or designee  will assess acne severity  on 
each subject’s face using FDA’s Investigator’s 
Global Assessment scale on acne severity  
Clinical Grading of Efficacy 
Parameters via digital images  (will be 
performed by Stephens  expert 
graders at the end of the study ): 
 Skin texture  
 Skin tone evenness  
 Clarity  
 Overall skin complexion  Investigator or designee  will assess efficacy through 
digital images using a modified Griffith’s 10 -point 
scale   
Clinical Grading of Tolerance  
Parameters:  
 Erythema  
 Dryness  
 Scaling  
 Stinging/Burning  Investigator or designee  will assess tolerance  using 
a 4-point scale . 
 Self-Assessment 
Questionnaires  6 to 25 item questionnaire  
 Digital Images  Digital photography using VISIA on the left, right, and 
center views under standard lightings: 1, 2, cross -
polarized, parallel polarized, UV -fluorescence 
lighting.  
 
Beauty shots (no head band/headrest/chinrest) will 
also be taken of the center view under visible light  
(Site 1 and 2 only)  
 Safety  Number of adverse events  
 
 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 11 of 44 
 1.1 Study Schematic  
 
  Baseline•Enroll ~ 130 to complete 100, 
•assessment/dispensation of study 
products
Week 1, Week 
2, Week 6, 
Week 12•Subject returns to testing facility for follow up
•Follow up phone calls will be made between Week 2 
and Week 6 or Week 6 and Week 12
Week 18•Subject returns to 
testing facility for test 
material distribution and 
compliance check
Week 24•Exit or Early Exit Visit 
and Subject returns 
productScreeningReview 
subject 
eligibility
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 12 of 44 
 TABLE OF CONTENTS  
TITLE PAGE  ................................ ................................ ................................ ................................ ...........  5 
1. Synopsis  ................................ ................................ ................................ ................................ ...........  6 
1.1 Study Schemati c ................................ ................................ ................................ .......................  11 
Table of contents  ................................ ................................ ................................ ................................ ..... 12 
2. Backround and Rationale  ................................ ................................ ................................ ..................  15 
3. Study Objectives and hypothesis  ................................ ................................ ................................ ........  15 
3.1.1.  Overall Purpose  ................................ ................................ ................................ ................  15 
3.1.2.  Hypothesis  ................................ ................................ ................................ .......................  15 
4. SELECTION AND DISPOSITION OF STUDY POPULATION  ................................ ...........................  15 
4.1 INCLUSION CRITERIA  ................................ ................................ ................................ ...........  15 
4.2 EXCLUSION CRITERIA  ................................ ................................ ................................ ..........  16 
4.3 CONCOMITANT THERAPIES  ................................ ................................ ................................ . 17 
4.3.1.  Authorized Therapies  ................................ ................................ ................................ ........  17 
4.3.2.  Prohibited Therapies  ................................ ................................ ................................ ..........  17 
5. STUDY PROCEDURES  ................................ ................................ ................................ ..................  17 
5.1 Protocol Waivers/Exemptions  ................................ ................................ ................................ .... 17 
5.2 Informed Consent Procedures  ................................ ................................ ................................ ..... 18 
5.3 Screening Procedures  ................................ ................................ ................................ ................  18 
5.3.1.  Demographics  ................................ ................................ ................................ ..................  18 
5.3.2.  Medical History  ................................ ................................ ................................ ................  19 
5.3.3.  Medication and Non -Drug Treatment History  ................................ ................................ ....... 19 
5.3.4.  Screen Failures  ................................ ................................ ................................ .................  20 
5.3.5.  Visit Windows  ................................ ................................ ................................ ..................  20 
5.3.6.  Adverse Weather Provision  ................................ ................................ ................................  20 
5.4 Visits and Examinations  ................................ ................................ ................................ ............  20 
5.4.1.  Screening (up to 14 days prior to baseline or may be combined)  ................................ ..............  20 
5.4.2.  Baseline (Screening and Baseline may be combined)  ................................ .....................  21 
5.4.3.  Week 1 ± 2 days from Baseline Visit and Week 2 ± 2 days from Baseline Visit  ................  21 
5.4.4.  Week 6 ± 3 days from Baseline Visit and Week 12 ± 3 days from Baseline Visit  ..............  22 
5.4.5.  Week 18 ± 3 days from Baseline Visit  ................................ ................................ .............  22 
5.4.6.  Week 24/Early Exit ± 3 days from Baseline Visit  ................................ .............................  22 
5.4.7.  Unscheduled Visits ................................ ................................ ................................ ............  23 
5.4.8.  Non-Clinic Days  ................................ ................................ ................................ ...............  23 
5.5 DISCONTINUED SUBJECTS  ................................ ................................ ................................ ... 24 
5.6 STUDY DURATION AND TERMINATION  ................................ ................................ ..............  24 
6. TREATMENT ADMINISTERED  ................................ ................................ ................................ ..... 24 
6.1 PRODUCT IDENTIFICATION AND USE  ................................ ................................ ..................  24 
6.2 ACCOUNTABILITY  ................................ ................................ ................................ ................  26 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 13 of 44 
 6.3 METHOD OF TREATMENT ASSIGNMENT  ................................ ................................ .............  27 
7. ADVERSE EVENTS  ................................ ................................ ................................ .......................  27 
7.1 DEFINI TIONS  ................................ ................................ ................................ .........................  27 
7.1.1.  Adverse Events (AE)  ................................ ................................ ................................ .........  27 
7.1.2.  Suspected Adverse Reaction (SAR)  ................................ ................................ .....................  28 
7.1.3.  Serious Adverse Events (SAE)  ................................ ................................ ............................  28 
7.1.4.  Severity  ................................ ................................ ................................ ...........................  28 
7.1.5.  Relationship to Study Products ................................ ................................ ............................  28 
7.1.6.  Causality assessment  ................................ ................................ ................................ .........  29 
7.2 REPORTING PROCEDURES  ................................ ................................ ................................ ... 29 
7.2.1.  Procedures for Reporting Adverse Events  ................................ ................................ .............  29 
7.2.2.  Procedure for Reporting a Serious Adverse Event  ................................ ................................ .. 29 
8. STATISTICAL METHODS PLANNED  ................................ ................................ ............................  30 
8.1 STATISTICAL AND ANALYTICAL PLANS  ................................ ................................ .............  30 
8.1.1.  Variables to be analyzed  ................................ ................................ ................................ .... 30 
8.1.2.  Populations Analyzed, Evaluability and Limitation / Evaluation of Bias  ................................ ... 31 
8.1.3.  Data Presentation and Graphics  ................................ ................................ ...........................  31 
8.2 SAMPLE SIZE DETERMINATION  ................................ ................................ ...........................  31 
9. STUDY CONDUCT CONDISERATIONS  ................................ ................................ .........................  31 
9.1 CLINICAL MONITORING  ................................ ................................ ................................ ....... 31 
9.2 QUALITY ASSURANCE / AUDIT / INSPECTION  ................................ ................................ ..... 32 
9.3 RECORD RETENTION  ................................ ................................ ................................ ............  32 
9.4 CHANGES IN STUDY CONDUCT / AMENDMENTS  ................................ ................................  33 
10. ETHICS  ................................ ................................ ................................ ................................ .........  33 
11. Study flow chart  ................................ ................................ ................................ ..............................  34 
11.1 Study flow chart  ................................ ................................ ................................ .......................  34 
12. REFERENCES  ................................ ................................ ................................ ...............................  35 
13. ATTACHMENTS  ................................ ................................ ................................ ...........................  35 
13.1 ELEMENTS OF INFORMED CONSENT  ................................ ................................ ...................  35 
Additional Elements of Informed Consent  ................................ ................................ ...............................  36 
13.2 Assessment Scales and Descriptions  ................................ ................................ ............................  37 
13.2.1.  Lesion Count  ................................ ................................ ................................ ....................  37 
13.2.2.  Investigator’s Global Assessment (IGA)  ................................ ................................ ...............  37 
13.2.3.  Clinical Grading of Efficacy Parameters through digital images  ................................ ...............  37 
13.2.4.  Clinical Grading of Tolerability Parameters  ................................ ................................ ..........  38 
13.2.5.  Digital images  ................................ ................................ ................................ ..................  39 
13.2.6.  Self-Assessment Questionnaires  ................................ ................................ ..........................  39 
Appendix I: Fitzpatrick Skin Type  ................................ ................................ ................................ ...........  44 
 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 14 of 44 
  
LIST OF ABBREVIATIONS AND DEFINITIONS OF TERMS  
AE  Adverse Event  
CRF Case Report Form  
eCRF  Electronic Case Report Form  
etc. et cetera  
e.g.  for example (Latin; exempla gratia)  
FDA The Food and Drug Administration  
GCP  Good Clinical Practice  
GLLP  Galderma Laboratories, L.P.  
HIPAA  Health Insurance Portability and Accountability Act of 1996  
ICH International Conference on Harmonization  
IEC Independent Ethics Committee  
IPL Intesnse Pulse Light  
IRB Institutional Review Board  
LOCF  Last Observation  Carried Forward  
N or n  Number  
OTC  Over -the-Counter  
% Percent  
P  Probability (as in significance level)  
Rx Prescription  
SAE Serious Adverse Event  
SAP Statistical Analyses Plan  
SD Standard deviation  
SOP  Standard Operating Procedure  
i.e.  that is (Latin:  id est)  
USV Unscheduled Visit  
  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 15 of 44 
 2. BACKROUND AND RATION ALE  
Acne is an inflammatory disease of the sebaceous gland that occurs during adolescence and 
persists into adulthood. Non -inflammatory acne lesions form when the opening of the follicle 
becomes blocked by the presence of dense keratin and sebum. Inflammatory acne lesions 
develop when the orifice of the follicle becomes completely occluded and bacteria replicate and 
excrete substances that induce an inflammatory reaction.  
Treatment with acne medications has been shown to help dissolve keratin plugs and help pr event 
the proliferation of bacteria in the sebaceous gland. This results in a reduction in the numbers of 
non-inflammatory and inflammatory acne lesions .1,2 
 
3. STUDY OBJECTIVES AND  HYPOTHESIS  
3.1.1.  Overall Purpose  
The purpose of this study is to evaluate the efficacy of 2 acne treatments  for 24 weeks 
of use in adult men and women with mild to moderate facial acne, at least 5 
inflammatory lesions, and at least 10 – 100 non -inflammatory lesions .  
 
3.1.2.  Hypothesis  
    After  24 weeks of 1 to 3 times per day use :  
 Subjects will demonstrate an improvement in acne lesion counts (inflammatory and 
non-inflammatory)  as ass essed by a  trained grader when compared to baseline . 
 Subjects will demonstrate an improvement in global assessment (IGA) as ass essed 
by a trained grader  over the course of the study , when compared to baseline.  
 Subjects will demonstrate an improvement in facial skin condition as assessed by 
a trained grader, through digital images, when compared to baseline.  
 Subjects will report high satisfaction with  the acne treatment  as measured through 
self-assessment questionnaire s. 
 
4. SELE CTION AND DISPOSITIO N OF STUDY POPULATIO N 
4.1 INCLUSION CRITERIA  
1. Men and women age 21 to 45  years at the time of enrollment . 
2. Individuals with mild to moderate acne  (score of 2 -3 on FDA Investigator’s Global 
Assessment Scale1) on the face.  
3. Individuals with at least 5 inflammatory lesions.  
4. Individuals with 10 – 100 non -inflammatory lesions.  
5. Individuals w illing to use th e test products as instructed for 24 weeks .  
6. Fitzpatrick skin type I -VI (refer to Appendix I: Fitzpatrick Skin Type ). 
7. Individuals w illing and able to comply with all of the time commitments and procedural 
requirements of the clinical trial protocol . 
8. Individuals willing to provide written informed consent including  photo release , Health 
Insurance Portability and Accountability Act (HIPAA) , and are able to read, speak, 
write, understand English  and are willing to share personal information and data, as 
verified by signing a written authorization at the screen ing. 
9. Willing to withhold all facial treatments during the course of the study including 
botulinum toxin, injectable fillers, microdermabrasion, IPL, peels, facials, laser 
treatments and tightening treatments.  Waxing and threading is allowed but not facial 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 16 of 44 
 laser hair removal.  
10. Males who are regular shavers and willing to shave on the day of the study visits (prior 
to clinic visits).  
 
11. Women of child bearing potential who are willing to take a urine pregnancy test prior 
to study enrollment, at week 24, and when dee med appropriate by the Investigator 
and/or Sponsor.  
12. Individuals of child b earing potential who use an acceptable method of contraception 
throughout the study.  Acceptable methods of birth control include:  
 
 Oral and other system contraceptives. Individuals must be on a stable use for 
3 months prior to study enrollment. Individuals on oral contraceptives must not 
alter their use, including dose or regimen for the duration of the study  
 Double barrier  
 Bilateral tubal ligation  
 Partner vasectomy  
 Abstinence  
13. Individuals willing to follow study requirements and report any changes in health status 
or medications, adverse event symptoms, or reactions immediately.  
14. Subjects must be stable on any medication they are taking for at least 30 days  
 
4.2 EXCLUSION CRITERIA  
1. Individuals diagnosed with allergies to topical acne products.  
2. Individuals having a condition and/or disease of the skin that the Investigator deems 
inappropriate for participation.  
3. Women  who are nursing, pregnant, or planning to become pregnant during the  study.  
4. Individuals who have pre -existing or dormant dermatologic conditions on the face 
(e.g., psoriasis, rosacea, eczema, seborrheic dermatitis, severe excoriations etc.) 
which in the opinion of the Investigator could interfere with the outcome of the st udy. 
5. Individuals with a history of immunosuppression/immune deficiency disorders 
(including (HIV infection or AIDS) or currently using immunosuppressive medications 
(e.g., azathioprine, belimumab, cyclophosphamide, Enbrel, Imuran, Humira, 
mycophenolate mof etil, methotrexate, prednisone, Remicade, Stelara.).  
6. Individuals with an uncontrolled disease such as asthma, diabetes, hypertension, 
hyperthyroidism, or hypothyroidism. Individuals having multiple health conditions may 
be excluded from participation even  if  the conditions are controlled by diet, medication, 
etc. at the Investigator’s discretion . 
7. Individuals who are currently participating in another facial usage study or have 
participated in a clinical trial within 4 weeks prior to inclusion into the stu dy. 
8. Individuals  with a history of skin cancer  on the face within the past 5 years . 
9. Individuals  with any planned surgeries and/or invasive medical procedures during the 
course of the study . 
10. Individuals who started hormone replacement therapies (HRT) or hormones for birth 
control less than 3 months prior to study entry or who plan on starting, stopping, or 
changing doses of HRT or hormones for birth control during the study.  
11. Individuals with facial sunburn or excessive tanned facial skin or that are not willing to 
avoid daily sun exposure on the face and the use of tanning beds or sunless tanning 
products for the duration of the study.  
12. Individuals with severe acne, acne conglobata, multiple nodules or cysts  (more than 
2). 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 17 of 44 
 13. Individuals currently taking a na tural or prescription testosterone blocker (e.g. saw 
palmetto, blask cohosh, chaste tree, chasteberry, spironolactone, drospirenone, 
progestins).  
14. Individuals currently on a testosterone booster or prescription testosterone (e.g. 
DHEA, tribulus, testosteron e cypionate, testosterone enanthate, Sustanon, 
testosterone propionate, testosterone phenylpropriate, Omnadren etc.).  
15. Individuals that are currently taking or have taken within the last 30 days oral or topical 
prescription medications for acne such as Doxy cycline, Minocycline, Clindamycin, 
Bactrim, Tetracycline, Erythromycin, Vibramycin and topical tretinoin.(Retin A Renova, 
Adapalene, Tazarotene), Azelaic acid, benzoyl peroxide, Dapsone, Sodium 
sulfacetamide, Differin, Epiduo.  
16. Individuals that have used or al isotretinoin (Accutane) within the past 6 -months.  
17. Individuals routinely using  (3x a week or more)  topical OTC acne product (e.g. benzoyl 
peroxide, salicylic acid, alpha hydroxyl, beta hydroxyl and/or poly -hydroxy products or 
medicated cleansers, wipes, masks, scrubs, gels and creams) within 14 days of the 
study entry.  
18. Individuals using or who have used any systemic medication considered to affect the 
course of acne, specifically, but not exclusively antibiotics or steroids within the last 30 
days  prior t o entry into the study.  
19. Individuals with excessive facial hair, including beard, mustache or goatee, or scars, 
which could interfere with evaluations by Investigator or designee.  
 
4.3 CONCOMITANT THERAPIES  
4.3.1.  Authorized Therapies  
Product A used once daily or Product B  used 1 to 3 times daily in AM/PM are required for this 
study.  Subject Product Kit will include: study drug, cleanser, moisturizing lotion, and moisturizer 
SPF.  
Unless listed under the exclusion criteria (Section 4.2) or in Prohibited Therapies (S ection 4.3.2), 
other therapies to treat ongoing conditions are authorized.  
 
4.3.2.  Prohibited Therapies  
The prohibited treatments are provided in the exclusion criteria in section 4.2. 
The decision to administer a prohibited medication/treatment should be made with the safety of 
the subject being the primary consideration. Whenever possible, GLLP should be notified before 
the prohibited medication/treatment is administered to discuss possible alternatives.  
If a subject receives prohibited therapy during the stud y, the subject may be allowed (at the 
discretion of the investigator / GLLP) to continue in the study for safety evaluation purposes, only.   
Galderma must be immediately notified in all inst ances of administration of prohibited meds.  
 
5. STUDY PROCEDURES  
5.1 Protocol Waivers/Exemptions  
Neither ICH nor the Food and Drug Administration (FDA) have defined the terms ‘Protocol 
Violations’ and ‘Protocol Deviations’. No “waivers” or “approvals” will be granted for protocol 
deviations or inclusion/exclusion criteria v iolations.  
Sites are instructed to report protocol deviations  to Stephens and Associates which will report the 
deviations to  the Independent Ethics Committee/Institutional Review Board (IEC/IRB) per their 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 18 of 44 
 IEC/IRB’s guidelines.  
Protocol non -compliance including lost to follow -up subjects should be reported to the site monitor 
as well as study management as soon as it is identified.  
5.2 Inform ed Consent Procedures  
An IEC/IRB approved informed consent template containing the required elements of an informed 
consent will be reviewed and approved by GLLP. Any changes made to these templates must be 
approved by GLLP prior to submission to the IEC/IRB for site approval. After approval by GLLP, 
the informed consent form must be submitted to  and approved by the IEC/IRB.  
It is the responsibility of the investigator to inform each subject, prior to the screening evaluation, 
of the purpose of the study, including possible risks and benefits, and to document the informed 
consent process in the s ubject’s research chart (and medical record, if applicable). Prior to entry 
into the study or initiation of any study related procedures, the subject must read, sign, and date 
the current IEC/IRB approved version of the consent form in accordance with loca l legal 
requirements and IEC/IRB requirements. The original  informed consent form is to be retained at 
the study site, and a copy is to be given to the subject.  
 
5.3 Screening  Procedures  
Screening will not be allowed at the site until the site has obtained all  applicable IEC/IRB 
approval s and a fully executed Clinical Study Agreement (CSA) . The sponsor will notify the site 
once screening may begin.  
Subjects must be consented using the IEC/IRB approved informed consent(s) prior to all study 
assessments and discontinuation of medication(s). Date and time of consent, as well as a 
summary of the consent discussion should be documented in the source.  
 
Each screened subject will be assigned a unique subject number .  The subject numbers will be 
assigned by site, w ith the first digit will be  used to indicate which site the subject was enrolled at 
and with an additional 2 numbers at the end being the subject number ( 3 digits total).  
 Site 1  (Stephens Texas)  examples:  101, 102, 103, etc.   
 Site 2  (Stephens Colorado)  examples:  201, 202, 203, etc.  
 Site 3  (Austin Institute for Clinical Research, Inc.) examples : 301, 302, 303, etc.  
 Site 4  (RCTS, Inc.) examples : 401, 402, 403, etc.  
 
5.3.1.  Demographics  
The following demographic parameters will be captured at the screening visit:  
 Age 
 Gender  
 Ethnicity and Race (subject self -identified)  
 Fitzpatrick Skin Type Classification  
 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 19 of 44 
 5.3.2.  Medical History  
The investigator or designee should complete a thorough review of the subject’s medical history 
for missing information. Medical conditions obtained at screening prior to enrollment should be 
captured and recorded in the subject’s baseline medical history.  All relevant “lifetime”  medical 
conditions are to be included.  Items to include are:  
 All ongoing medical diseases/condition, including chronic, intermittent, or recurrent 
disease.  
 Any condition that requires ongoing therapy.  
 All disease/conditions resolv ed in the past 30 days.  
 Any condition that, in the opinion of the investigator, is clinically relevant including 
diseases for which the subject required surgery.  
 Subjects with conditions that, in the opinion of the investigator, may put the subject at risk , 
may confound study results, or may interfere with participation in the study must be 
excluded from the study.  
        Contact GLLP Medical Lead  if further clarifications are needed.  
Name/Title  Affiliation/Tel./Fax  
Marie -Jose Rueda , MD  
Rx Medical Direct or 
 Galderma Laboratories, L.P.  
Tel : (817) 961 -5227 
5.3.3.  Medication and Non -Drug Treatment History  
Previous drug and non -drug therapies should be assessed as related to the eligibility criteria listed 
in the protocol. Information on previous therapies (includ ing herbal products) that have been 
stopped within 6 months prior to visit screening should be recorded on the CRF.  
Other medications to treat concurrent medical conditions ARE permitted provided the 
dose is stable for at least 30 days prior to screening  and throughout the study.  
Any therapy used by the subject during the study will be considered a  concomitant 
medication/non -drug treatment. Concomitant medications and non -drug treatments obtained at 
screening and baseline prior to enrollment should be cap tured and recorded in the subject’s 
baseline medication and non -drug treatment history. Every attempt should be made to keep  all 
concomitant medication/therapy  dosing and regimen s constant during the study. Any change to 
this therapy should be noted on the  CRFs. If applicable, an Adverse Event CRF/eCRF should be 
completed for any subject starting new concomitant medications, unless the therapy is used for 
prophylaxis.  
Concomitant medications and non -drug therapies during the course of the study are defined  as: 
Any new therapy received by the subject after subject enrollment, including:  
– Drug therapies, such as Rx medications, OTC products  (excluding OTC personal 
hygiene  products) , birth control medication, homeopathic preparations, vitamins, 
sunscreens, etc.  **Fitzpatrick Skin Type Classification (Please  select one) : 
  I –   Always burns; never tans  
  II –  Burns easily; tans minimally  
  III – Burns moderately; tans  gradually to light brown  
  IV – Burns minimally; tans well to moderate brown  
  V –  Rarely burns; tans profusely to dark brown  
  VI – Never burns; tans profusely to black  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 20 of 44 
 – Non-drug therapies, such as medical/surgical procedures.  
– Any changes to existing therapies, such as changes in dose or formulation.  
The concomitant therapies are to be recorded at each visit on the appropriate CRF/eCRF.  
 
5.3.4.  Screen Failures  
If a consented sub ject fails to meet all of the requirements to participate in the study, or decides 
not to participate up to the point of enrollment at visit 1 (baseline), the subject will be considered 
a screen failure. The reason for screen failure should be documented a ppropriately in the source  
document and the CRF/eCRF . 
5.3.5.  Visit Windows  
Visit windows as outlined below are allowed during the study : 
 Screening (up to 14 days prior to baseline visit)  
 Baseline    
 Week 1 ±2 days from Baseline Visit  
 Week 2 ± 2 days from Baseline Visit 
 Week 6 ± 3  days from Baseline Visit  
 Week 12 ± 3  days from Baseline Visit  
 Week 1 8 ± 3 days from Baseline Visit  
 Week 24 ± 3 days from Baseline Visit  
5.3.6.  Adverse Weather Provision  
Study visits may be delayed if adverse weather conditions present a risk to the safety of persons 
traveling to the investigative site. Visits will be resumed immediately with the earliest acceptable 
improvement of travel conditions and staff availability. GLLP will be notified of changes in 
scheduled visit dates.  
5.4 Visits and Examinations  
5.4.1.  Screening (up to 14 days prior to baseline or may be combined)  
1. Review and explain the purpose and nature of the study to the subject.  
2. Obtain Subject Informed Consent.  
 Have the subject read, sign and date an IEC/IRB approved informed consent 
including photo and video release, HIPAA authorization, and applicable state Bill 
of Rights.  
 Document the informed consent process in the source documents and CRF/.  
 Give a signed copy o f the informed consent form to subject.  
3. Assign the subject a unique screening number. Update screening and enrollment log.  
4. Have subjects acclimate for at least 15 minutes in ambient temperature and humidity -
conditions (68 -75ºF and 35 -65% humidity)  
5. Confirm  subject meets inclusion/exclusion criteria  including mild to moderate facial acne 
(score of 2 -3 on FDA Investigator’s Global Assessment Scale), at least 5 inflammatory 
lesions, and 10 -100 non -inflammatory lesions and have this recorded by the Investigato r 
or designee .  
6. Have the Investigator  or designee  complete the tolerance grading . 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 21 of 44 
 7. Obtain demographic information and medical history, including information on all 
medications/ therapies used within the last 6 months. Inform the subject as to the allowed 
and prohibited concomitant medications (see Section 4.2 and 4.3.2). If the candidate 
subject qualifies  and is female of child -bearing potential , conduct a urine pregnancy test. 
Candidate female subjects with negative results , females of non -child-bearing pote ntial,  
or candidate males that qualify will proceed to the next step.  
8. Candidate subject’s eligibility will be overseen by a dermatologist or MD physician.  The 
dermatologist will confirm that the subject is suitable for the test materials.  Those that 
quali fy will be asked to return for the baseline visit.  
9. Record any AEs that occur after the subject has signed the informed consent form.  
 
Note:  Subject screening and baseline visits may occur on the same day if site logistics permit.  
 
5.4.2.  Baseline (Screening and B aseline may be combined)  
1. Obtain information on any changes in medical health and/or the use of concomitant 
medications/therapies to ensure the subject’s eligibility in the study.   
2. Record any AEs that are observed or reported, including those of changes in concomitant 
medication dosing/therapies.  
3. Confirm subject still meet inclusion/exclusion criteria  including mild to moderate facial 
acne (score of 2 -3 on FDA Investigator’s Global Assessment Scale), at least 5 
inflammatory lesions, and 10 -100 non -inflammat ory lesions and have this recorded by the 
Investigator or designee .  
4. Subject’s eligibility and health will be re -reviewed. Those that still pass eligibility 
requirements will be enrolled into the study and assigned a subject number.  
5. Have the Investigator  or designee  complete the tolerance grading . 
6. Subjects will participate in digital images procedures.  
7. Subject will be randomly assigned to receive Product A or Product B  as determined by a 
randomization schedule provided by Stephens . Study products will be d ispensed and 
subjects will be provide d instructions on how to properly use the study products.   
8. Subjects will be provided with a daily diary to record product application . 
9. Emphasize the importance of compliance with the instructions and application 
requirements . 
10. Instruct the subject to bring back the dispensed study products at the next visit  
 
5.4.3.  Week 1 ± 2 days from Baseline Visit  and Week 2 ± 2 days from Baseline Visit  
1. Obtain information on any changes in medical health and/or the use of concomitant 
medications/therapies to ensure the subject’s eligibility in the study.  
2. Record any AEs that are observed or reported, including those of changes in concomitant 
medication dosing/therapies.  
3. Have the subject acclimate for at least 15 minutes in ambient temperature and humidity 
condition (68 -75ºF and 35 -65% humidity).  
4. Have the investigator  or designee  complete the lesion count (inflammatory and non -
inflammatory).  
5. Have the Investigator  or designee  complete the Investigator Global Assessments  (IGA)  
on acne severity . 
6. Have the Investigator  or designee  complete the tolerance grading . 
7. Have the subject complete the self-assessment q uestionnaire . 
8. Emphasize the importance of compliance with the instructions and application 
requirements . 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 22 of 44 
 9. Daily diaries will be collected , reviewed for compliance of the study product application.  
The diaries will be returned to the subjects at week 1. At week 2, diaries will be retained 
by the testing facility and  new d iaries will be distributed  to the subjects.  
10. Collect, weigh , and re -dispense study product.  
11. Instruct the subject to bring back the dispensed study product s at the next visit.   
 
5.4.4.  Week 6  ± 3 days from Baseline Visit  and Week 12 ± 3 days from Baseline Visit  
1. Obtain information on any changes in medical health and/or the  use of concomitant 
medications/therapies to ensure the subject’s eligibility in the study.  
2. Record any AEs that are observed or reported, including those of changes in concomita nt 
medication dosing/therapies.  
3. Have the subject acclimate for  at least  15 minu tes in ambient temperature and humidity 
condition (68 -75ºF and 35 -65% humidity). ‘  
4. Have the investigator or designee complete the lesion count (inflammatory and non -
inflammatory).  
5. Have the Investigator  or designee  complete the Investigator Global Assessmen ts (IGA) 
on acne severity . 
6. Have the Investigator  or designee  complete the tolerance grading . 
7. Have subjects participate in digital images procedures.  
8. Have the subject complete the self -assessment questionnaire.  
9. Emphasize the importance of compliance with th e instructions and application 
requirements.  
10. Daily diaries will be collected , reviewed for compliance of the study product application , 
and retained by the testing facility . New d iaries will be distributed to the subjects.  
11. Collect, weigh , and re -dispense study product. Products will be retained and new products 
will be dispensed as necessary.  
12. Instruct the subject to bring back the dispensed study products at the next visit.   
 
Follow -up phone calls will be made between Week 6 and Week 12 to inquire how subjects are 
progressing and if subjects have enough study product to use until the next visit.  
 
5.4.5.  Week 18 ± 3 days from Baseline Visit  
1. Obtain information on any changes in medical health and/or the use of concomitant 
medications/therapies to ensure the subject’s eligibility in the study.  
2. Record any AEs that are observed or reported, including those of changes in concomitant 
medication dosing/therapies.  
3. Emphasize the importance of compliance with the instructions and application 
requirements.  
4. Daily diaries will be collected , reviewed for compliance of the study product application , 
and retained by the testing facility . New diaries will be distributed to the subjects.  
5. Collect, weigh, and re -dispense study product.  
6. Instruct the subject to bring b ack the dispensed study products at the next visit.   
 
5.4.6.  Week 24/Early Exit ± 3  days from Baseline Visit  
1. Obtain information on any changes in medical health and/or the use of concomitant 
medications/therapies to ensure the subject’s eligibility in the study.  
2. Record any AEs that are observed or reported, including those of changes in concomitant 
medication dosing/therapies.  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 23 of 44 
 3. Conduct a urine pregnancy test on women of child -beraing potential.  
4. Have the subject acclimate for at least 15 minutes in ambient temperat ure and humidity 
condition (68 -75ºF and 35 -65% humidity).  
5. Have the investigator or designee complete the lesion count (inflammatory and non -
inflammatory).  
6. Have the Investigator  or designee  complete the Investigator Global Assessments  (IGA) 
on acne severit y. 
7. Have the Investigator  or designee  complete the tolerance grading . 
8. Have subjects participate in digital images procedures.  
9. Have the subject complete the self -assessment questionnaire.  
10. Daily diaries will be collected , reviewed for compliance of the study product application , 
and retained by the testing facility .  
11. Collect  and weigh  study product.  
12. Complete the Exit Form CRF/eCRF.  
 
After study completion, a trained grader from Stephens will evaluate the digital images taken at 
baseline, week 6, week 12, and week 24 for clinical grading of efficacy parameters.  
 
5.4.7.  Unscheduled Visits  
Any visit that occurs between the regularly scheduled visits must be documented in the 
Unscheduled Visit (USV) pages of the CRF/eCRF. During all USVs, the following procedures will 
be conducted:  
1. Obtain information on any changes in medical health and/or the use of concomitant 
medications/therapies to ensure the subject’s eligibility in the study.  
2. Record any AEs that are observed or reported, including those of changes in concomitant 
medication dosing/therapies.  
3. Daily diaries will be collected and reviewed for compliance o f the study product application . 
4. Have the investigator  or designe e complete the lesion count (inflammatory and non -
inflammatory).  
5. Have the Investigator  or designee  complete the Investigator Global Assessments (IGA)  
on acne severity . 
6. Have the Investigator  or designee  complete the tolerance grading . 
7. Have the subject acclimate for at least 15 minutes in ambient temperature and humidity 
condition. Upon acclimation, have  subjects participate in digital images procedures.  
8. Have the subject complete the self -assessment questionnaire.  
9. Emphasize the importance of compliance with the instructions and application 
requirements.  
10. Collect and weigh study products.  
 
These procedures are required at USVs;  however at the investigator discretion additional 
assessments may be performed and recorded on the USV CRF /eCRF .  If a subject is discontinued 
at an USV, refer to Section 5.5 for guidance.  
5.4.8.  Non-Clinic Days  
Instruct s ubjects to use Product A once daily or Product B 1-3 times a day  following the same 
instructions discussed during the clinic visit. Subjects will be instructed to cleanse their face and 
remove any make -up (if applicable) 30  minites prior to each clinic visits.  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 24 of 44 
 5.5 DISCONTINUED SUBJECTS  
Any subject is free to discontinue h is/her participation in this study at any time and for whatever 
reason, specified or unspecified, and without prejudice.   
Subjects who discontinue the study prematurely should be fully evaluated, whenever possible.  
The procedures designated for the early  exit visit (Section 5.4.7) should be completed for all 
prematurely discontinued subjects and the appropriate CRFs should be completed.  
All subjects who prematurely discontinue the study should have the reason carefully documented 
by the investigator on t he exit CRF/eCRF, and, if applicable, on the adverse event CRF/eCRF. In 
no case, shall a subject who prematurely discontinues (who has been included and has had a  
subject  identification number assigned), be replaced by another subject. In the case of prema ture 
discontinuation due to an AE, the investigator should ensure that the subject receives appropriate 
follow -up and therapy for their condition. All data gathered on the subject related to AE resolution 
will be made available to the Sponsor and/or regula tory authorities . 
An investigator may decide to discontinue a subject from the study for safety reasons or when it 
is in the best interest of the subject. GLLP may also decide to prematurely terminate or suspend 
the study or the participation of a subject in the study. All data gathered on the subject prior to 
termination should be made available to GLLP.  
The Exit Form must be completed and one of the following reasons for discontinuation must be 
identified:  
 Adverse Event  
 Subject Request  
 Protocol Violation  
 Lost to Follow -up 
 Other  
If reason for discontinuation is “other”, the subject will be questioned to definitively rule out the 
possibility of an AE.  
5.6 STUDY DURATION AND TERMINATION  
Study duration for each subject is approximately 24 weeks . It is estimated a maximum of 10 
month s will elapse between first subject first visit and last subject last visit.  
The investigator may terminate the study at his/her study site at any time with appropriate 
notification to GLLP. Likewise, GLLP may terminat e prematurely the participation of a particular 
study site (e.g., for non -enrollment or non -compliance with protocol, regulation or Good Clinical 
Practice) or terminate prematurely the entire study (e.g., for safety, quality of study product, 
regulatory, e fficacy or logistics reasons) at any time with appropriate notification.  
6. TREATMENT ADMINISTER ED 
At baseline, qualified subjects will be enrolled and randomized to receive Product A or Product B . 
Throughout the study, the investigator will be responsible for the accounting of the study product  
and will ensure that the study product  is not used in any unauthorized manner.  
6.1 PRODUCT IDENTIFICATION AND USE  
Study Product: Product A   
Form  Gel 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 25 of 44 
 Instructions for use  Dispense a nickel size amount of product and apply as a thin layer 
to the entire face or any other affected areas of the skin once daily, 
after washing gently with a mild soap -less cleanser and drying the 
area.  
Mode of Administration:  Topical  
Duration of Use:  24 Weeks  
Quantity:  1 
How supplied:  Kit 
Storage and Handling  Product to be stored at USP Controlled Room Temperature 
conditions: 68°F – 77°F (20°C – 25°C) with excursions permitted 
between 59°F – 86°F (15°C – 30°C)  
Study Product:  Product B   
Form  Gel 
Instructions for use  Clean the skin thoroughly before applying this product. Cover the 
entire affected area with a thin layer one to three times daily. 
Because excessive drying of the skin may occur, start with one 
application daily, then gradually increase to two or three daily if 
needed or as directed by a doctor. If bothersome dryness or peeling 
occurs, reduce application to once a day or every other day.  
Mode of Administration:  Topical  
Duration of Use:  24 Weeks  
Quantity:  2 
How supplied:  Kit 
Storage and Handling  Product to be stored at Room Temperature conditions: 68°F – 77°F 
(20°C – 25°C). Keep product away from excess heat and moisture.  
 
Facial Cleanser  
Form  Gel 
Instructions for use  Massage a small  amount onto wet skin. Rinse  
Mode of Administration:  Topical  
Duration of Use:  24 Weeks  
Quantity:  1 
How supplied:  Kit 
Storage and Handling  Fragile, handle with care. Keep from freezing and extreme heat.  
Moisturizing Lotion  
Form  Lotion  
Instructions for use  After applying the product, use moisturizer on the entire face. Apply 
daily to dry skin as needed or as directed by physician.  
Mode of Administration:  Topical  
Duration of Use:  24 Weeks  
Quantity:  1 
How supplied:  Kit 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 26 of 44 
 Storage and Handling  Fragile, handle with care. Store at controlled room temperateure; 
68°F – 77°F (20°C – 25°C) with excusrsions permitted between 59°F 
-86°F (15°C – 30°C).  
Facial Moisturizer SPF 30  
Form  Cream  
Instructions for use  Apply lilberally 15 minutes before sun exposure. Use a water 
resistant sunscreen if swimming or sweating. Reapply at least every 
2 hours.  
Mode of Administration:  Topical  
Duration of Use:  24 Weeks  
Quantity:  1 
How supplied:  Kit 
Storage and Handling  Fragile, handle with care. Keep from freezing and extreme heat.  
 
General instructions:  
Use all products as instructed. Cleanser, test material, and moisturizer should be used as a 
regimen.  
Avoid extended periods of sun exposure, all use of tanning beds, and sunless tanning products 
for the duration of the study. Extra care should be taken to wear protective clothing, including 
sunglasses, and avoid sun exposure from 10 AM to 4 PM.  
Continue use of all regular brands of color cosmetics, makeup remover, and use the assigned 
test material for the duration of the study.  Individuals must refrain from using any acne  products 
and beginning the use of any new facial products other than the assigned test material. Use of 
moisturizing foundation  and waterproof SPF  will be acceptable as long as the subject has a history 
of safe usage of the foundation  and waterproof SPF . 
 
Subjects will be instructed to use Product A once daily or Product B  1-3x a day.   
6.2 ACCOUNTABILITY  
Upon receipt of the study products, the investigator  or designee will conduct an inventory. In 
accordance with federal regulations, the investigator must agree to keep all study products in a 
secure location with restricted access. Designate d study personnel will provide the study products 
to the subjects in accordance with the protocol. A daily temperature log will be maintained 
documenting appropriate study product storage conditions.  
During the study, the investigator must maintain records  of study treatment dispensation for each 
subject. This record must be made available to the study monitor for the purposes of verifying the 
accounting of clinical supplies. Any discrepancies and/or deficiencies between the observed 
disposition and the wri tten account must be recorded along with an explanation.  
Compliance will be assessed by study staff at each visit. Subjects will be considered compliant 
with the treatment product if they use at least 80% of the expected applications for each of the 
test product during participation in the study.  Subjects will be considered non -compliant if usage 
is over 1 20%. 
Subjects will complete a daily diary recording test material applications  and comments  during 
the course of the study. Diaries will be reviewed and test materials will be visually inspected at 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 27 of 44 
 each post -baseline study visit to evaluate treatment compliance. Additionally, test material units 
will be weighed prior to distribu tion and at week 1, week 2, week 6, week 12 , week 18, and 
week 24 .  
 
If subjects do not return their diary or test materials during an interim visit, a verbal confirmation 
will be obtained for usage compliance and will be documented as a note to file.  The subject will 
be reminded to return their diary and test materials at the next study visit.  
 
6.3 METHOD OF TREATMENT ASSIGNMENT  
Prior to the start of the study, Stephens  will generate a randomization list to establish treatment 
assignment to 1 of the treatment cells (Cell 1 and  Cell 2) , which will be balanced between sites . 
Stephens will provide the product label coding according to the provided randomization.  
 
7. ADVERSE EVENTS  
Throughout the course of the study, all adverse events will be monitored and reported on an 
adverse event CRF /eCRF  without omitting any requested and known information. When AEs 
occur, the main concern is the safety of the study subjects. At the time of the informed consent 
signature, each subject must be given the name and phone number of study site per sonnel for 
reporting AEs and medical emergencies. This information is included in the Informed Consent.  
At each visit, after the subject has had the opportunity to spontaneously mention any problems, 
the investigator  or designee  should inquire about AEs by  asking the standard questions  (e.g): 
“Have you had any health problems since your last study visit?”  
“Have there been any changes in the medicines you take since your last study visit?”  
AEs should be reported as a result of an untoward (unfavorable and un intended) change from 
baseline in a subject's medical health following signature of the Informed C onsent . 
Changes from baseline in any protocol -specific parameter evaluated during the study are to be 
reviewed by the investigator. In addition, the subject’s  responses to any questionnaire utilized 
during the study are to be reviewed by the investigator. Any untoward (unfavorable and 
unintended) change from baseline in a protocol -specific parameter or questionnaire response is 
to be reported as an AE. These cl inically relevant changes will be reported regardless of causality.  
7.1 DEFINITIONS  
7.1.1.  Adverse Events (AE)  
Adverse event means any untoward medical occurrence associated with the use of a study 
product in humans, whether or not considered study product related.  
An adverse event (also referred to as an adverse experience) can be any unfavorable and 
unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally 
associated with the use of a study product, and does not imply any judgment about causality. An 
adverse event can arise with any use of the study product (e.g., off -label use, use in combination 
with another study product) and with any route of administration, formulation, or dose, including 
an overdose.  
Thus any new sign, symptom or di sease, or clinically significant increase in the intensity of an 
existing sign, or symptom should be considered as an adverse event.  
Notes:  
Any new clinically relevant sign or symptom suffered by the subject, which appears after the study 
procedures should  also be reported as an adverse event.  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 28 of 44 
 7.1.2.  Suspected Adverse Reaction (SAR)  
Suspected adverse reaction means any adverse event for which there is a reasonable possibility 
that the study product caused the adverse event. ‘Reasonable possibility’ means there is evidence 
to suggest a causal relationship between the study product and the adverse event.  
Any adverse event, whether or not it is related to the study product, will be reported on the AE 
CRF along with the date of onset, the severity, the relationship with the study product and the 
outcome.  
If the subject discontinues due to  an AE, the AE CRF and exit CRF must be completed.  
7.1.3.  Serious Adverse Events (SAE)  
An adverse event or suspected adverse reaction is considered “serious” if in a view of either the 
investigator or sponsor, it results in any of the following outcomes:  
 death,  
 life-threatening adverse event (the event places the subject at immediate risk of death),  
 inpatient hospitalization or prolongation of existing hospitalization,  
 a persistent or significant disability/incapacity or substantial disruption of the ability to 
conduct normal life functions, or  
 a congenital anomaly/birth defect  
 
Additionally:  
Important medical events that are based on appropriate medical judgment may jeopardize the 
subject and may require medical or surgical intervention to prevent one of the outcomes listed 
above.  
Note :  The term “life -threatening” refers to an adverse event or suspected adverse reaction if, in 
the view of either the investigator or sponsor, its occurrence places the subject at immediate risk 
of death. It does not include an a dverse event or suspected adverse reaction that, had it occurred 
in a more severe form, might have caused death.  
Hospitalization solely for the purpose of diagnostic tests, even if related to an AE, elective 
hospitalization for an intervention which was a lready planned before the inclusion of the subject 
in the study, and admission to a day -care facility may not themselves constitute sufficient grounds 
to be considered as a serious adverse event. Hospitalization is defined as admission to a hospital 
for gr eater than 24 hours.  
7.1.4.  Severity  
Severity is a clinical determination of the intensity of an adverse event.  
The severity assessment for an AE is to be completed using the following definitions as a guideline 
for all AEs occurring during clinical trials conduc ted or sponsored by Galderma, Laboratories, 
L.P.: 
Mild:   Awareness of sign or symptom, but easily tolerated  
Moderate:  Discomfort, enough to cause interference with usual activity  
Severe:  Incapacitating with inability to work or perform usual activity  
 
7.1.5.  Relationship to Study Products  
The relationship assessment for an AE is to be completed using the following definitions as a 
guideline for all AEs occurring during clinical trials conducted or sponsored by Galderma 
Laboratories, L.P.:  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 29 of 44 
 7.1.6.  Causality assessment  
The Investigator is to determine whether there is a reasonable causal relationship between the 
trial/test products(s) and/or procedures and the event. Medical judgment should be used to 
determine the relationship, considering all relevant factors including  the pattern of event, temporal 
relationships, positive de -challenge or re -challenge, relevant medical history, and confounding 
factors such as co -medication or concurrent diseases.  
 
The relationship assessment for an event is to be completed using the fol lowing definitions:  
 Reasonable possibility : According to the reporting Investigator, there is a reasonable 
possibility (i.e., suggestive evidence or arguments) that there is a causal relationship 
irrespective of the dose administered between the trial/test  product and/or procedures and 
the event,  
 No Reasonable Possibility : No suggestive evidence or arguments can be identified 
regarding a causal relationship between the trial/test product and/or procedures and the 
event.  
The expression “reasonable causal rel ationship” is meant to convey in general that there are facts 
or arguments to suggest a causal relationship . 
 
Assessment of casualty  must be completed by the investigator.  
 
7.2 REPORTING PROCEDURES  
7.2.1.  Procedures for Reporting Adverse Events  
The collection of AEs  will begin when a subject signs the informed consent up to the final visit. At 
each visit, the investigator or designee will question the subject about AEs using questions taking 
care not to influence the subject’s answer (e.g. “Have you noticed any chang e in your health?”). 
Directed questioning and examination will then be done when appropriate.  
Any AE, whether or not it is related to the study product, will be reported on the AE CRF/eCRF 
along with the date of onset, the severity, the relationship with the study product and the outcome 
without omitting any requested and known information. Additional information may be requested 
under certain circumstances to ensure accurate reporting.  
Every time a concomitant medications/therapy is administered or prescr ibed during the study, an 
AE CRF/eCRF will be completed if appropriate and the reason for the treatment noted.  
When an AE persists after a subject exits the study , the investigator will ensure an appropriate 
follow -up of the subject until the investigator/GLLP agrees the event is satisfactorily resolved or 
has reached a stable clinical endpoint.  
 
Sites 2, 3, and 4 will report AEs to Site 1 by e -mail to areaka@stephens -associates.com . Site 1 
will report AEs to GLLP.  
 
7.2.2.  Procedure for Reporting a Serious Adverse Event  
For any SAE, occurring during the study, whether or not related to the study product, expected or 
not, the investigator is to take the following steps:  
1. Take prompt and appropriate medical action, if necessary. The safety of study subjects is 
the first priority.  
2. Inform GLLP of the event by fax (682 -831-9197) and email at 
pharmacovigilanceUS@galderma. com within 24 hours, and discuss further steps to be 
taken. Galderma representatives and their contact information are provided in the 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 30 of 44 
 communication plan that accompanies this protocol. Also inform Stephens & Associates 
by e-mail at areaka@stephens -associates.com , the same as GLLP.  
3. Complete the AE CRF/eCRF with as much information as possible.  
4. Complete the SAE Form. Fax the completed form accompanied by the demography 
CRF/eCRF, the Medical History CRF/eC RF, the Previous and Concomitant 
Medication /Therapies CRF/eCRF, the AE CRF/eCRF, and any other relevant information 
(e.g. test results) immediately to GLLP at 682 -831-9197.  
5. Monitor and record the progress of the event until it resolves or reaches a clinical ly stable 
outcome, with or without sequel. Every effort should be made to obtain further safety 
details and follow -up information from the subject and his/her doctors within limits 
described by local laws and regulations.  
6. Obtain and maintain in his/her fil es all pertinent medical records, information, and medical 
judgments from who may have assisted in the treatment and follow -up of the subject. If 
necessary, contact the subject’s personal physician or hospital to obtain further 
information.  
7. Inform GLLP of the ongoing progress and final outcome of the event. Send a revised or 
updated SAE Form, if appropriate to the above fax number.  
8. Comply with the applicable regulatory requirement(s) related to the reporting of serious 
adverse events to the regulatory autho rity (ies) and the IRB.  
 
8. STATISTICAL METHODS PLANNED  
8.1 STATISTICAL AND ANALYTICAL PLANS  
A separate document , named the Statistical Analysis Plan (SAP), will be developed by Stephens 
during the conduct of the study and approved  by GLLP  prior to database lock. It will contain a 
more detailed and technical description of specific data conventions, calculations and of statistical 
procedures for executing the analyses that are specified in the sections of the protocol below.  
Any changes to  the statistical analyses planned in the protocol will be justified and documented 
in the SAP if they were decided before database lock. Any change made to the SAP after the 
database lock will be documented in the final clinical study report as deviations from the planned 
analysis.  
8.1.1.  Variables to be analyzed  
The following variables will be analyzed or summarized:  
8.1.1.1.  Primary Variables  
 Percent Change in Total Lesions at Week 12  
8.1.1.2.  Secondary  Variables  
 Change in lesion count from baseline.  
 Change in Investigator ’s Global Assessment (IGA)  
 Change in clinical grading of efficacy parameters through digital images from 
baseline . 
 Subject self-assessment questionnaire  at Weeks 1, 2, 6, 12, and 24 .   
 Change in tolerance grading from baseline.  
 
8.1.1.3.  Safety Variables  
 Incidence of adverse events  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 31 of 44 
 8.1.1.4.  Data Transformations  
No data transformations are planned.  
8.1.2.  Populations Analyzed, Evaluability and Limitation / Evaluation of Bias  
Statistical analyses will be performed based on the  following subject populations .  
8.1.2.1.  Intent -to-Treat (ITT) Population  
The ITT population is defined as all subjects who are randomized and have at least one post -
treatment administration evaluation. This is the primary population for efficacy analyses. All 
primary efficacy variables and secondary efficacy variable s will be analyzed based on the ITT 
population. LOCF (Last Observation Carried Forward ) will be used to impute missing efficacy data 
for this population.  
8.1.2.2.  Safety Population  
The safety population is defined as all subjects who are enrolled and receive at least one dose of 
study product. In practice, only the subjects who return their study product unopened will be 
excluded from the safety population. Safety variables will be a nalyzed based on the safety 
population.  
8.1.3.  Data Presentation and Graphics  
The subject disposition, demographics, baseline characteristics, compliance (number of missed 
applications, total number of applications, etc.), visit dates including informed consent date, 
inclusion/exclusion criteria, previous therapies and concomitant therapies by treatment will be 
listed or summarized. All primary and safety variables listed will be summarized at each visit. The 
categorical variables will be summarized by frequency and percentage for each response 
category (N, %). The continuous variables will be summarized using means, medians, minimum, 
maximum, and standard deviations (SD) for each visit.  
Additional summary tables will be provided for AEs that are considered serio us (SAEs), related 
to the study product, and AEs leading to discontinuation. All AE summary tables are based on the 
number of subjects in safety population who have experienced AE(s). For a given AE, a subject 
will be counted once, even if he or she has ex perienced multiple episodes for that particular AE . 
8.2 SAMPLE SIZE DETERMINATION  
Sample size is determined according to Sponsor’s recommendation.  
  
9. STUDY CONDUCT CONDIS ERATIONS  
9.1 CLINICAL MONITORING  
The conduct of the study will be closely monitored by representatives of GLLP following GCP, 
ICH guidelines, applicable SOPs,  regulatory guidelines and  all local regulations. The clinical 
investigation will be monitored to ensure that:  the rights and well -being of the subjects are 
protected; the reported dat a are accurate, complete and verifiable from applicable source 
documents; and the study is conducted in accordance with the currently approved protocol and 
any other study agreements, GCP, and all applicable regulatory requirements. The investigator 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 32 of 44 
 will a llow the GLLP representatives to have access to all study records, CRF, corresponding 
subject medical records, and any other documents considered source documentation. The 
investigator also agrees to assist the representatives, if required, which can inclu de AE reporting.  
DATA COLLECTION  
Investigators must keep accurate records of all subjects' visits and all procedures done, being 
sure to include all pertinent study related information from which CRF/eCRF data will be recorded. 
Data for this study may be recorded in the subject's chart (e.g. source documents / electronic 
records) or if approved by the GLLP directly into CRF. If electronic records are maintained, the 
method of verification must be determined in advance of starting the study. A statement sho uld 
be made indicating that the subjects have been enrolled in protocol GLI.04.SPR.US 10329  and 
have been provided with a copy of the signed informed consent. The process of administering the 
informed consent must also be documented. Any and all side effect s and AEs with the 
concomitant therapies associated must be thoroughly documented. Results of any diagnostic 
tests conducted during the study should be included in the source documentation. Pertinent 
telephone conversations with the subjects and/or GLLP co ncerning the study will be documented 
and kept on file.  
It is required that the author of an entry in the source documents be identifiable. Direct access to 
all source documentation (medical records) must be allowed for the purpose of verifying that the 
data recorded in the CRF/eCRF are consistent with the original source.  
Only designated individuals may complete the CRF. The principal investigator will review the 
reported data and certify that the CRF are accurate and complete.  
After monitoring has occur red at the clinical site(s) and the CRF have been reviewed, additional 
data clarifications and/or additions may be needed including AE reporting. Data clarifications 
and/or additions are documented and are part of each subject’s CRF.  
9.2 QUALITY ASSURANCE / AU DIT / INSPECTION  
To ensure compliance with GCP and all applicable regulatory requirements, GLLP may conduct 
a quality assurance audit of the site records, and the regulatory agencies may conduct a 
regulatory inspection at any time during or after completio n of the study. The investigator must 
agree to grant the auditor(s) and inspector(s) direct access to all relevant documents and to 
allocate their time and the time of their staff to discuss any findings/relevant issues.  
9.3 RECORD RETENTION  
The investigator is required to maintain up -to-date, complete regulatory documentation as 
indicated by GLLP and the investigator’s files will be reviewed as part of the ongoing study 
monitoring. The records must be easily accessible when needed (e.g., for a Galderma 
Labora tories L.P.’s audit or regulatory inspection) and must be  available for review in conjunction 
with assessment of the facility, supporting systems, and relevant site personnel. Financial 
information is not subject to regulatory inspection and should be kept  separately.  
GLLP will inform the investigator of the time period for retaining the site records in order to comply 
with all applicable regulatory requirements. The minimum retention time will meet the strictest 
standard applicable to a particular site, a s dictated by local laws/regulations, GLLP SOPs, and/or 
institutional requirements.  
The investigator should take measures to prevent accidental or premature destruction of these 
documents. If the investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the responsibility. GLLP must be notified in writing of the name and address of the new 
custodian.  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 33 of 44 
 9.4 CHANGES IN STUDY CONDUCT / AMENDMENTS  
No amendment will be done for modification(s) due to change in logistical or administrative aspect 
of the study (e.g., change in monitors, change of telephone numbers). In such a case, the 
appropriate institution(s) and/or person(s) will be notified of th e changes.  
Modification of the protocol is prohibited without prior written agreement in the form of a protocol 
amendment. All amendments will be created by GLLP and must be approved by the IEC/IRB prior 
to implementation except when required to mitigate i mmediate safety risks or when the changes 
involve only logistical or administrative revisions.  
Amendments may necessitate that the informed consent and other study -related material be 
revised. If the consent form is revised, all patients/subjects currentl y enrolled in the study may be 
required by the IRB/IEC to sign the approved, revised informed consent form.   
 
10. ETHICS  
This study will be conducted in accordance with the HELSINKI Declaration (1964) and it’s TOKYO 
(1975), VENICE (1983), HONG -KONG (1989), SOM ERSET WEST (1996) and EDINBURGH 
(2000) , Washington (2002). Tokyo (2004), Seoul (2008), and Brazil (2013)  amendments, the ICH 
Good Clinical Practice (GCP) guidelines, FDA Code of Federal Regulations (CFR), Health 
Insurance Portability and Accountability Act  (HIPAA) and local regulatory requirements. The 
investigator and all clinical study staff will conduct the clinical study in compliance with the 
protocol. The investigator will ensure that all personnel involved in the conduct of the study are 
qualified to  perform their assigned responsibilities through relevant education, training, and 
experience.  
Before clinical study initiation, this protocol, the informed consent form with any other written 
information given to subjects, and any advertisements planned f or subject recruitment must be 
approved by an IEC/IRB. The investigator must provide documentation of the IEC/IRB approval 
to GLLP . The approval must be dated and must identify the applicable protocol, amendments (if 
any), informed consent form, all applic able recruiting materials, written information for subject, 
and subject compensation programs. The IEC/IRB will be provided with  any periodic safety 
updates, and all other information required by local regulation and/or the IEC/IRB. At the end of 
the study , the investigator will notify the IEC/IRB about the study’s completion. The IEC/IRB also 
will be notified if the study is terminated prematurely. Finally, the investigator will report to the 
IEC/IRB on the progress of the study at intervals stipulated by the IEC/IRB.  
Voluntary informed consent will be obtained from every subject prior to the initiation of any 
screening or other study -related procedures. The investigator must have a defined process for 
obtaining consent. Specifically, the investigator, or d esignee, will explain the clinical study to each 
potential subject and the subject must indicate  voluntary consent by signing and dating the 
approved informed consent form. The subject must be provided an opportunity to ask questions 
of the investigator, a nd if required by local regulation, other qualified personnel. The investigator 
must provide the subject with a copy of the consent form written in a language the subject 
understands. The consent document must meet all applicable local laws and will provid e subjects 
with information regarding the purpose, procedures, requirements, and restrictions of the study, 
along with any known risks and potential benefits of the study product, the available 
compensation, and the established provisions for maintaining c onfidentiality of personal, 
protected health information. Subjects will be told about the voluntary nature of participation in 
the study and will be provided with contact information for the appropriate individuals should 
questions or concerns arise during  the study. The subject also will be told that their records may 
be accessed by appropriate authorities and Sponsor -designated personnel. The investigator must 
keep the original, signed copy of the consent and must provide a duplicate copy to each subject.  
  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 34 of 44 
  
11. STUDY FLOW CHART  
  
11.1 Study flow chart  
 
 
PROCEDURES  Study Visits  
Visit 1  
Screening a Visit 2 
Baseline a 
 Visit 
3 
Week 
1 
(±2 
Days) 
/Early 
Exit Visit 
4 
Week 
2 
(±2 
Days) 
/Early 
Exit Visit 
5 
Week 
6 
(±3 
Days) 
/Early 
Exit Visit 6 
Week 
12 
(±3 
Days)/Early 
Exit Visit 7 
Week 
18 
(±3 
Days)/Early 
Exit Visit 8  
Week 
24 
(±3 
Days)/Early 
Exit Unscheduled 
Visit (USV)c 
Informed Consent  X         
Inclusion/Exclusion Criteria  X X        
Demographics  X         
Previous Therapies & Procedures  X         
Medical History  X         
Urine pregnancy test  X       X X 
Diaries Dispensed/Collected   X  X X X X X X 
Concomitant  therapies & 
procedures  X X X X X X X X X 
Lesion count  X X X X X X  X X 
IGA X X X X X X  X X 
Clinical Grading of Efficacy 
Parameters through digital images    X   X X  X X 
Clinical Grading of Tolerance 
Parameters  X X X X X X  X X 
Imaging procedures   X   X X  X X 
Self-Assessment  Questionnaire    X X X X  X X 
Test Products dispensing   X   X X X X X 
Adverse Events b   X X X X X X X X 
Exit Form         X X 
a Screening and Baseline visit may be combined.  
b Adverse events are to be collected starting from the signing of the Informed Consent Form.   
c If a subject is discontinued at Week 1, Week 2, Week 6, Week 12, Week 18 or USV, Week 24/Exit or Early 
Exit Procedures are to be completed  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 35 of 44 
 12. REFERENCES  
  
1. U.S. Food and Drug Administration. Guidance for industry: acne vulgaris: developing 
drugs for treatment. September 2005. http://www.fda.gov.  
2. Shai, A., Maibach, HI, Baran, R. Baran.  Acne in Handbook of Cosmetic skin Care. 
Publisher Martin Duntiz Ltd., Chapter 9, 81 -100, 2001.  
3. Rizer, RL, Mills, OH, Trookman, NS. The assessment of acne: a re -evaluation of grading 
strategies. Scientific Poster, Annual Meeting of the Am. Acad. Dermatol (2001).  
4. Griffiths CE, Wang TS, Hamilton TA, Voorhees JJ, Ellis CN. A photonumeric scale for the 
assessment of cutaneous photodamage. Arch Dermatol. 1992 Mar;128(3):347 -351. 
 
 
13. ATTACHMENTS  
Attachment 12.1 – Elements of Informed Consent  
Attachment 1 2.2 – Assessment Scale  and Descriptions  
13.1 ELEMENTS OF INFORMED CONSENT  
The following information must be provided to each subject in obtaining informed consent. If 
written consent is being obtained, the subject (or subject’s legal representative) should be 
provided with a copy of  the signed written informed consent.  
1. State that the study involves RESEARCH.  
a. Explain the PURPOSES of the research  
b. State the expected DURATION of the subject’s participation  
c. Explain the trial treatments  
d. Describe the PROCEDURES to be followed  
e. Identify any EXPERIMENTAL procedures  
f. Explain the subject’s responsibilities  
2. Describe any reasonably foreseeable RISKS OR DISCOMFORTS to the subject (skin 
irritation)  
3. Describe any BENEFITS to the subject or to others which may reasonably be expected 
from research  
4. Note a ppropriate ALTERNATIVE procedures or courses of treatment, if any that might be 
advantageous to the subject.  
5. Describe the extent, if any, to which CONFIDENTIALITY of records identifying the subject 
will be maintained. Note that the monitors, the auditors, the IRB and the Food and Drug 
Administration (FDA) will be granted access to the subject’s original medical records for 
verification of clinical trial procedures and/or data without violating the confidentiality of the 
subject, to the extent permitted by t he applicable laws and regulations and that by signing 
a written informed consent form, the subject or the subject’s legally acceptable 
representative is authorizing such access.  
6. Describe the anticipated prorated payment, if any, to the subject for participating in the 
trial. 
7. For research involving more than minimal risk, explain if any COMPENSATION or medical 
treatments are available should injury occur. If so, explain (a) what they consist of, OR (b) 
where further information may be obtained.  
8. Tell whom to contact for ANSWERS to pertinent questions about (a) the research and (b) 
research subject’s rights.  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 36 of 44 
 9. State that:  
a. participation is VOLUNTARY  
b. refusal to participate will involve NO PENALTY or loss of benefits to which the 
subject is otherwise entitl ed, and  
c. the subject MAY DISCONTINUE participation at any time without penalty or loss 
of benefits to which the subject is otherwise entitled  
 
Additional Elements of Informed Consent  
When appropriate, one or more of the following elements of information sha ll also be provided to 
each subject.  
1. A statement that the particular treatment or procedure may involve risks to the subject 
which are currently unforeseeable.  
2. Any additional costs to the subject that may result from participation in the research.  
3. The consequences of a subject’s decision to withdraw from the research and procedures 
for orderly termination of participation by the subject.  
4. A statement that significant new findings developed during the course of the research 
which may relate to the subject ’s willingness to continue participation will be provided  to 
the subject or the subject’s legally acceptable representative in a timely manner.  
5. The approximate number of subjects involved in the study.  
6. A statement that a description and/or summary of this  clinical trial will be available on 
www.clinicaltrials.gov, as required by U.S. Law. The subject may review the information 
posted in this web site at any time. The web site will not include information that can 
identify the subject.  
References :  
21 CFR P art 50.25 – Protection of Human Subjects, Basic Elements of Informed Consent  
International Conference on Harmonization Guidance for Industry E6 Good Clinical Practice: 
Consolidated Guidance, 4.8 Informed Consent of Trial Subjects (April 1996)  
The informed  consent requirements in these regulations are not intended to pre -empt any 
applicable federal, state, or local laws.  
 
  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 37 of 44 
 13.2 Assessment Scales  and Descriptions  
13.2.1.  Lesion Count  
Clinic Day Assessments: Screening/ Baseline, Week 1, Week 2, Week 6, Week 12 , Week 24   
A trained grader  will count and record the number of open comedones, closed comedones 
papules, and pustules  on each subject’s face. Note that papules and pustules are classified as 
inflammatory acne lesions while open and closed comedones are classified as non-inflammatory 
lesions.  
 
Acne lesion counts will be assessed globally on the face for each of the following facial 
locations/quadrants: forehead, left cheek, chin (including the area above the upper lip), and right 
cheek. Lesions on the nose, under the jaw line or along the hairline (including eye brows) will not 
be included in the counts.3 
 
13.2.2.  Investigator ’s Global Assessment (IGA)   
Clinic Day Assessments: Screening/Baseline, Week 1, Week 2, Week 6, Week 12, and Week 
24  
A trained grader will evaluate each subject’s global face for Investigator’s Global Improvement 
Assessment.  
 
FDA Investigator’s Global Assessment of Acne Severity scale  
0 Clear  No inflammat ory or non -inflammatory lesions  
1 Almost 
Clear  Rare non -inflammatory lesions with no more than one small 
inflammatory lesion  
2 Mild Greater than Grade 1, some non -inflammatory lesions with no 
more than a few inflammatory lesion (papules/pustules only, no  
nodular lesions)  
3 Moderate  Greater than Grade 2, up to many non -inflammatory lesions and 
may have some inflammatory lesions, but no more than one 
small nodular lesion  
4 Severe  Greater than Grade 3, up to many non -inflammatory and 
inflammatory lesions, but no more than a few nodular lesions  
 
13.2.3.  Clinical Grading of Efficacy Parameters through digital images  
Clinic Day Assessments: Baseline, Week 6, Week 12 , and Week 24   
Stephen’s trained grader will evaluate each digital images for clinical grading of efficacy 
parameters. The efficacy parameters will be assessed globally on each subject’s face  using a 
modified Griffiths ’ 10-point scale4 according to the following numerical definitions (half -point 
scores may be used as necessary to more accurately describe the skin condition):  
0 = none (best possible condition)  
1 to 3 = mild  
4 to 6 = moderate  
7 to 9 = sev ere (worst possible condition)  
 
The following parameters will be evaluated using the indicated scale anchors:   
 
Parameter  0 = 9 = 
Skin texture  Smooth, even looking skin Rough, uneven looking skin 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 38 of 44 
 Parameter  0 = 9 = 
texture  texture  
Skin tone  evenness  Even skin tone  Severely uneven skin tone  
Clarity   Translucent skin appearance  Dull/flat matte skin appearance  
Overall skin complexion  Excellent  Poor  
 
13.2.4.  Clinical Grading of Tolerability Parameters  
Tolerability evaluations will be performed at screening, baseline, and weeks 1, 2, 6, 12,  and 24. Local 
cutaneous tolerability will be evaluated by assessing the signs and symptoms of erythema, dryness, 
and scaling, and by subject reporting of the degree of stin ging/burning on the global face (treatment 
area).  
 
For subject assessments of subjective irritation, subjects will report the degree of any parameters that 
they typically experience when using a product similar to the test material(s) at the baseline visit. At 
post-baseline time points, subjects will repor t the degree of any of these symptoms they have 
experienced since the previous time point.  
 
The following static (without reference to any prior visits) scales and definitions will be used for 
tolerability evaluations (with half-point scores used as neces sary to better describe the clinical 
condition):  
 
Objective Irritation Parameters  
 
Erythema  
0 = None  No erythema of the treatment area  
1 = Mild  Slight, but definite redness of the treatment area  
2 = Moderate  Definite redness of the treatment area  
3 = Severe  Marked redness of the treatment area  
 
Dryness  
0 = None  No dryness of the treatment area  
1 = Mild  Slight, but definite dryness of the treatment area  
2 = Moderate  Definite dryness of the treatment area  
3 = Severe  Marked dryness of the treatment area 
 
Scaling  
0 = None  No scaling of the treatment area  
1 = Mild  Barely perceptible, fine scales in limited areas of the treatment area  
2 = Moderate  Fine scaling generalized to all areas of the treatment area  
3 = Severe  Scaling and peeling of skin over all areas of the treatment area  
 
Subjective Irritation Parameters  
 
Burning /stinging 
0 = None  No burning /stinging  of the treatment area  
1 = Mild  Slight burning /stinging  sensation of the treatment area; not really bothersome  
2 = Moderate  Definite warm, burning /stinging  of the treatment area that is somewhat 
bothersome  
3 = Severe  Hot burning /marked stinging  sensation of the treatment area that causes definite 
discomfort and may interrupt daily activities and/or sleep  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 39 of 44 
 13.2.5.  Digital images  
Clinic Day Assessments : Baseline, Week 6, Week 12 , and Week 24   
Prior to photography procedures, clinic personnel will ensure that subjects have a clean face with 
no makeup as described in the study procedures. Subjects will remove any jewelry from the 
area(s) to be photographed and equilibrate for at least 15 minutes to ambient conditions (68-75ºF 
and 35 -65% humidity) within the clinic before any photographs  are taken.  
 
VISIA Imaging:  
Subjects will be provided with a black or gray matte headband to keep hair away fro m the face 
and instructed on proper headband placement. Subjects will be provided with a black matte shirt 
or a black or gray matte cloth will be draped over the subjects’ clothing. Subjects will be instructed 
to adopt neutral, non -smiling expressions with  their eyes gently closed. Subjects will be carefully 
positioned for each photograph, for the center, right, and left side views.  
 
Full-face digital images will be taken of each subject (right side, left side, and center views) using 
the VISIA CR photo -station (Canfield Imaging Systems, Fairfield, New Jersey) with a Canon Mark 
II 5D  or 6D  digital SLR camera (Canon Incorporated, Tokyo, Japan) under the following lighting 
conditions:     
Standard lighting 1  
Standard lighting 2  
Cross -polarized  
Parallel polarized  
UV fluorescence  
 
Visible Light Imaging (Beauty shot)  
For subjects completing at sites 1 and 2 (Stephens’ Texas and Colorado locations), d igital images 
will be taken of each subject’s face using visible light. Full -face images will be tak en of each 
subject’s center view. Subjects will not be wearing any headband or using any headrest/chinrest. 
Subjects will be instructed to adopt neutral, non -smiling expressions with their eyes open .  
13.2.6.  Self-Assessment  Questionnaire s 
Clinic Day Assessments:  Week 1, Week 2, Week 6, Week 12, and Week 24  
Subjects will be asked to complete a self-assessment questionnaire.  This  questionnaire has a 
5-point Likert Response Scale (1=Strongly Agree; 5=Strongly Disagree).  Responses for each 
item will be transforme d into percent agreement (percentage of subjects with a score of 1 or 2) 
and presented descriptively.  The individual items will be ask ed at the indicated time points : 
 
Questions  Visit 2: 
Week 1  Visit 3: 
Week 2  Visit 4: 
Week 6  Visit 5: 
Week 12  Visit 7: 
Week 24 
I experienced noticeable improvement in my 
skin tone        X X 
I experienced noticeable improvement in my 
skin texture        X X 
I experienced noticeable improvement in my 
skin radiance        X X 
My skin has a more youthful appearance        X X 
My skin is clearer skin using this treatment    X X X X 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 40 of 44 
 I feel my skin is now clear      X X X 
This treatment works faster than my previous 
acne treatment.  X X       
This treatment is strong enough to give me 
clear, acne free skin.        X X 
The treatment helped to reduce redness and 
inflammation caused by my acne.      X X X 
I feel that this treatment deep cleans and 
unblocks my pores.  X X X     
This treatment visually minimized my pore 
size.      X X X 
I noticed an improvement in my acne. 
Strongly agree to Strongly disagree  X X     X 
This treatment reduces my acne without 
leaving behind dry, flakey skin.      X X X 
I have noticed I had fewer breakouts than my 
previous treatments.                                                      X X X X X 
My skin looks better than before      X X X 
This treatment breaks my cycle of acne and 
keeps my skin clear                                                          X X 
I saw improvement in the overall health of my 
skin since starting the regimen     X   X X X 
My skin looks noticeably smoother and 
healthier      X X   
The areas of my skin where I used to have 
acne is now clear and radiant after daily 
treatment.                                                                                                                                              X X X X 
I feel better about my skin  since I’ve started 
the treatment regimen      X X X 
I feel more confident since I’ve started the 
treatment      X X X 
Has your quality of life improved now that 
you have started using this product?        X X 
I would continue using this treatment beyond 
24 weeks as a regular part of my skincare 
routine.          X 
What is your overall satisfaction with the 
regimen?      X X X 
I have noticed a positive difference in the 
appearance of my skin with this regimen.      X X X 
This once a day regimen is easy to use every 
day.  X   X     
I liked the feel of this product.  X        
I would recommend this product to others.        X X 
My acne is as clear as if I went to a doctor or 
received a prescription.        X X 
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 41 of 44 
 I don’t feel the need for a prescription after 
using this product.        X X 
Total:  7 6 16 24 25 
 
 
 
  
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 43 of 44 
   
 PROTOCOL  
11 February 2016  
This document contains confidential, proprietary information.  
Page 44 of 44 
 APPENDIX I: FITZPATR ICK SKIN TYPE  
 
The Fitzpatrick skin classification is based on the skin’s unprotected response to the first 30 to 45 minutes 
of sun exposure after a winter season without sun exposure.  The categories of skin types are as follows:  
 
I White; very fair; red or blonde hair; blue eyes; freckles  Always burns easily; never tans  
II White; fair; red or blonde hair; blue, hazel, or green eyes  Always burns easily; tans minimally  
III Cream white; fair with any eye or hair color; very common  Burns moderately; tans gradually  
IV Brown; typical Mediterranean white  skin Burns minimally; always tans well  
V Dark Brown; mid -eastern skin types, black hair, olive skin  Rarely burns; tans profusely  
VI Black; black hair, black eyes, black skin  Never burns; deeply pigmented  
 
 
 